Northern Trust Corp Buys 81,252 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Northern Trust Corp lifted its stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 22.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 435,972 shares of the company's stock after acquiring an additional 81,252 shares during the quarter. Northern Trust Corp owned about 0.82% of Zevra Therapeutics worth $3,636,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. acquired a new position in shares of Zevra Therapeutics during the 4th quarter worth about $94,000. Invesco Ltd. raised its holdings in Zevra Therapeutics by 19.6% in the 4th quarter. Invesco Ltd. now owns 18,384 shares of the company's stock valued at $153,000 after acquiring an additional 3,007 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Zevra Therapeutics by 51.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 20,565 shares of the company's stock valued at $172,000 after acquiring an additional 6,966 shares in the last quarter. SG Americas Securities LLC raised its holdings in Zevra Therapeutics by 54.6% in the 4th quarter. SG Americas Securities LLC now owns 23,500 shares of the company's stock valued at $196,000 after acquiring an additional 8,302 shares in the last quarter. Finally, Corebridge Financial Inc. raised its holdings in Zevra Therapeutics by 16.9% in the 4th quarter. Corebridge Financial Inc. now owns 26,294 shares of the company's stock valued at $219,000 after acquiring an additional 3,801 shares in the last quarter. Institutional investors own 35.03% of the company's stock.

Analyst Upgrades and Downgrades

ZVRA has been the subject of several recent research reports. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price target on shares of Zevra Therapeutics in a report on Thursday, March 13th. Citigroup reaffirmed an "outperform" rating on shares of Zevra Therapeutics in a report on Wednesday, May 14th. Canaccord Genuity Group upped their price target on Zevra Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a report on Thursday, March 13th. JMP Securities set a $18.00 price target on Zevra Therapeutics in a report on Wednesday, March 12th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 price target on shares of Zevra Therapeutics in a report on Wednesday, May 14th. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $22.29.

Insider Buying and Selling

In other Zevra Therapeutics news, Director John B. Bode acquired 10,000 shares of the company's stock in a transaction that occurred on Wednesday, March 19th. The shares were acquired at an average price of $7.96 per share, with a total value of $79,600.00. Following the purchase, the director now owns 40,000 shares of the company's stock, valued at $318,400. This represents a 33.33% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 2.40% of the stock is currently owned by company insiders.

Zevra Therapeutics Stock Performance

ZVRA stock opened at $8.57 on Friday. The business's fifty day moving average is $7.58 and its 200-day moving average is $8.09. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The company has a market cap of $468.61 million, a P/E ratio of -4.35 and a beta of 1.87. Zevra Therapeutics, Inc. has a twelve month low of $4.20 and a twelve month high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.15. The business had revenue of $20.40 million for the quarter, compared to the consensus estimate of $16.96 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. During the same quarter last year, the business posted ($0.40) EPS. Equities research analysts forecast that Zevra Therapeutics, Inc. will post -1.95 EPS for the current year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.